. 2023 May 3;53(5):1244–1253. doi: 10.55730/1300-0144.5690

Table 1.

Demographic data of the patients in the study.

n		24⁰ week		25⁰–26^0–7 weeks		27⁰–28^0–7weeks		29⁰–30^0–7 weeks		31⁰–32^0–7 weeks		33⁰–34^0–7 weeks		35^0–7 week		p
n		%	n	%	n	%	n	%	n	%	n	%	n	%
Antenatal steroid administration	None/Unknown (n=207)	0	0.0	12	20.0	11	16.4	38	31.7	44	27.8	78	37.1	24	38.1	0.005
	One dose (n=170)	1	33.3	22	36.7	13	19.4	23	19.2	41	25.9	53^c	25.2	17^c	27.0
	Two doses (n=304)	2	66.7	26	43.3	43	64.2	59	49.2	73	46.2	79^c	37.6	22^c	34.9
Mode of delivery	Vaginal Delivery (n=35)	0	0.0	3	5.0	1	1.5	5	4.2	13	8.2	13	6.2	0^e,^f	0.0	0.046
Mode of delivery	Cesarean (n=646)	3	100.0	57	95.0	66	98.5	115	95.8	145	91.8	197	93.8	63^e,^f	100.0	0.046
Resuscitation requirement	None (n=58)	0	0.0	2	3.3	0	0.0	8	6.7	13	8.2	25	11.9	10^c	15.9	<0.001
	‘’PBV-t piece (n=525)	0	0.0	31	51.7	40	59.7	94^a,^b	78.3	135 ^a,^b	85.4	175 ^a,^b	83.3	50 ^a,^b	79.4
	Intubation (n=98)	3	100.0	27	45.0	27	40.3	18 ^a,^b,^c	15.0	10 ^a,^b,^c	6.3	10 ^a,^b,^c,^d	4.8	3 ^a,^b,^c	4.8
Sex	Female (n=58)	2	66.7	34	56.7	28	41.8	69	57.5	58^d	36.7	98	46.7	32	50.8	0.015
Sex	Male (n=360)	1	33.3	26	43.3	39	58.2	51	42.5	100 ^d	63.3	112	53.3	31	49.2	0.015
SIMV-PS-VG^*	Available (n=152)	3	100.0	38	63.3	42	62.7	29^b,^c	24.2	19 ^b,^c	12.0	16 ^b,^c,^d	7.6	5 ^b,^c	7.9	<0.001
SIMV-PS-VG^*	None (n=529)	0	0.0	22	36.7	25	37.3	91 ^b,^c	75.8	139 ^b,^c	88.0	194 ^b,^c,^d	92.4	58 ^b,^c	92.1	<0.001
HFO ^Ɨ	Available (n=62)	2	66.7	20	33.3	13	19.4	14^b	11.7	4^a,^b,^c,^d	2.5	7 ^a,^b,^c	3.3	2 ^a,^b	3.2	<0.001
HFO ^Ɨ	None (n=619)	1	33.3	40	66.7	54	80.6	106^b	88.3	154 ^a,^b,^c,^d	97.5	203 ^a,^b,^c	96.7	61 ^a,^b	96.8	<0.001
Surfactant administration	Available (n=151)	3	100.0	38	63.3	42	62.7	36^b,^c	30.0	13 ^b,^c,^d	8.2	15 ^b,^c,^d	7.1	4 ^b,^c,^d	6.3	<0.001
Surfactant administration	None (n=530)	0	0.0	22	36.7	25	37.3	84 ^b,^c	70.0	145 ^b,^c,^d	91.8	195 ^b,^c,^d	92.9	59^b,^c,^d	93.7	<0.001
Surfactant administration dose	One dose (n=87)	2	66.7	17	44.7	22	52.4	23	63.9	9	69.2	10	66.7	4	100.0	0.246
Surfactant administration dose	Two doses (n=64)	1	33.3	21	55.3	20	47.6	13	36.1	4	30.8	5	33.3	0	0.0	0.246
Necrotizing enterocolitis	None (n=670)	3	100.0	56	93.3	66	98.5	117	97.5	157	99.4	208	99.0	63	100.0	0.124
Necrotizing enterocolitis	Stage 2 and Stage 3 NEC (n=11)	0	0.0	4	6.7	1	1.5	3	2.5	1	0.6	2	1.0	0	0.0	0.124
Bronchopulmonary Dysplasia(BPD)	Available (n=60)	3	100.0	31	51.7	17^b	25.4	5^a,^b,^d	4.2	4 ^a,^b,^d	2.5	0 ^a,^b,^d	0.0	0 ^a,^b,^d	0.0	<0.001
Bronchopulmonary Dysplasia(BPD)	None (n=621)	0	0.0	29	48.3	50^b	74.6	115 ^a,^b,^d	95.8	154 ^a,^b,^d	97.5	210 ^a,^b,^d	100.0	63 ^a,^b,^d	100.0	<0.001
Number of dexamethasone-furosemide treatment/cures for BPD	No cure (n=632)	0	0.0	33a	55.0	54^a,^b	80.6	117^a,^b, ^c	97.5	156^a,^b,^c	98.7	209^a,^b, ^c	99.5	63^a,^b,^c	100.0	<0.001
	Single cure(n=42)	2	66.7	24	40.0	11	16.4	3 ^a,^b,^c	2.5	1 ^a,^b,^c	0.6	1 ^a,^b,^c	0.5	0 ^a,^b,^c	0.0
	Two cure (n=7)	1	33.3	3	5.0	2	3.0	0^a,^b	0.0	1^a,^b	0.6	0^a,^b	0.0	0^a,^b	0.0
Retinopathy of Prematurity	None (n=666)	2	66.7	50	83.3	65	97.0	118^b,^c	98.3	158 ^b,^c	100.0	210 ^b,^c	100.0	63 ^b,^c	100.0	<0.001
	^¥VEGF (n=8)	0	0.0	4	6.7	2	3.0	2	1.7	0^b	0.0	0^b	0.0	0^b	0.0
	Laser (n=7)	1	33.3	6	10.0	0^a,^b	0.0	0 ^a,^b	0.0	0 ^a,^b	0.0	0 ^a,^b	0.0	0 ^a,^b	0.0
Intracranial hemorrhage	None (n=661)	0	0.0	55^a	91.7	61 ^a,^b	91.0	116 ^a,^b	96.7	157 ^a,^b	99.4	209 ^a,^b	99.5	63 ^a,^b	100.0	<0.001
Intracranial hemorrhage	Stage 2 and/or 3 hemorrhage (n=20)	3	100.0	5^a	8.3	6 ^a,^b	9.0	4 ^a,^b	3.3	1 ^a,^b	0.6	1 ^a,^b	0.5	0 ^a,^b	0.0	<0.001
clinical/proven sepsis	None (n=513)	0	0.0	22	36.7	37	55.2	78^a,^b	65.0	139^a,^b,^c	88.0	183^a,^b,^c	87.1	54^a,^b		<0.001
clinical/proven sepsis	clinical/proven sepsis (n=168)	3	100.0	38	63.3	30	44.8	42^a,^b	35.0	19^a,^b,^c	12.0	27^a,^b,^c	12.9	9^a,^b		<0.001

“PBV: Positive pressure ventilation,

SIMV-VG-PSV; Synchronous intermittent mechanical ventilation + volume guarantee + pressure support ventilation,

^Ɨ:

HFO: High frequency oscillation,

^¥

VEGF; vascular endothelial growth factor; It shows the differences with

24,

25–26,

27–28,

29–30,

31–32 and

33–34 weeks.